(AIM:DMTR ) said it has secured contracts with five new major customers over the last two months for its powerful computer aided synthesis design tool, ICSYNTH.
ICSYNTH enables chemists to generate synthetic pathways for a target molecule, allowing innovation with alternative or novel synthetic routes that may have not been considered.
In total, ICSYNTH customer numbers have more than doubled during 2020, with the group receiving 100% customer renewals which it said has added to its underlying revenue base.
DeepMatter, which is aimed at digitising chemistry, said the new customers include several global leading pharmaceutical, agrisciences, biotech and contract research organisations.
Retrosynthesis, which is the process of “deconstructing” a target molecule into readily available starting materials, is a growing area of the Life Sciences Research & Development space and therefore provided ‘an increasing opportunity’ for ICSYNTH, the group noted.
Shares in DeepMatter have traded relatively flat over the past three months to open this morning 19.14% higher at 2.08p.
The Company told investors that development work has recently been completed on a new User Interface for the tool, facilitating greater ease of use, and new algorithms have been introduced to filter out erroneous data from any data source.
This includes proprietary data in Electronic Laboratory Notebooks which could lead to improved synthesis predictions resulting in better productivity and time management.
"We are delighted to be supplying our powerful retrosynthesis and forward planning tools to these leaders in their field, expanding our customer base not only in the Pharmaceutical industry but also within the agrisciences and CRO sectors,” said CEO, Mark Warne.
He added, "With machine learning and cloud technologies both powerful tools in the race to accelerated drug discovery, we see a growing opportunity for both our ICSYNTH and DigitalGlassware™ platforms and look to the future with confidence."
Deepmatter, formerly Cronin Group, is a UK-based firm engaged in the digitisation of chemical space and chemical drug discovery, through its subsidiary, Cronin 3D Limited.
Follow News & Updates fromhere:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
(Sharecast News) - London stocks were well into positive territory at the close on Friday, with banks pacing the advance after well-received results from Barclays, as investors shrugged off news that the UK's economic recovery was stalling.
Gunsynd, an investment firm operating within the natural resources sector, announced that it has invested C$0.25 million (around £0.146 million) into precious metals royalty and streaming company Empress Royalty Corp. The group said the move complements existing investments in the precious metals sector, adding new commodity exposure to silver.
Clinical stage drug development firm, Evgen Pharma, has been given the green light to kick-start its STAR trial which will investigate whether its lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19.
Braveheart Investment Group, the AIM-listed investment firm, said its investee company, Pharm2Farm ("P2F"), will launch the sale of a new antiviral face mask that has a ‘kill rate’ of over 90% for up to 7 hours for COVID-19 by the end of the year.
London-listed Sensyne Health, the UK-based clinical AI company, announced that it has signed a research collaboration agreement with US pharmaceutical company Bristol Myers Squibb ("BMS"), marking its fourth successive partnership with a major pharma company.